DUBLIN--(BUSINESS WIRE)--The "Overactive Bladder - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Global sales for OAB are projected to increase from $2.2 billion in 2020 to $2.8 billion in 2030 at a CAGR of 2.7% with sales of Myrbetriq accounting for a market share of 52.6%.

First-line pharmacotherapy for OAB typically consists of orally administered antimuscarinics, a highly genericized drug class. In the 2010s the beta-3 adrenergic receptor agonists (beta-3 agonists) Myrbetriq (mirabegron) and Gemtesa (vibegron) were approved for the treatment of OAB.

Myrbetriq is the market leader in OAB and is available across all eight major markets (8MM) while, to date, Gemtesa has only been approved in Japan and the US. The neuromuscular blocking agent Botox (onabotulinumtoxinA) also represents an alternative therapeutic option for patients refractory to oral drugs.

Key Highlights

• The OAB market is characterized by significant untapped potential. OAB is highly prevalent but diagnosis and treatment rates remain low owing to factors such as social stigma and lack of knowledge among healthcare professionals.
• The prevalence of OAB is expected to increase over the forecast period owing to factors such as aging populations, which will expand the treatment pool.
• The market value is expected to decline in the early-to-mid forecast period (2020-2025) as patent expiries for key products constrain drug sales. However, the launch of several pipeline products will provide a boost to market sales in the mid-to-late forecast period (2025-2030).

Scope

• Overview of OAB, including classification, epidemiology, etiology, pathophysiology, diagnosis, and disease management.
• Topline OAB therapeutics market revenue for 2020-2030 (includes annual cost of therapy and anticipated sales for major late-stage pipeline drugs).
• Key topics covered include current treatment options, clinical trials landscape, unmet needs and opportunities, R&D strategies, drivers and barriers of market growth, current and future players, and market outlook.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global OAB market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Topics Covered:

1 Overactive Bladder: Executive Summary

1.1 Overactive Bladder Market to Experience Moderate Growth, Reaching $2.8 Billion by 2030

1.2 R&D Landscape Shifts Away from Orally Administered Antimuscarinics

1.3 Significant Unmet Needs to Persist Throughout Forecast Period

1.4 Urovant Sciences Has Potential to Launch the First Gene Therapy in Overactive Bladder

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of OAB

4.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Presentation

4.4.5 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Comorbidity

4.4.6 Diagnosed Prevalent Cases of OAB

4.5 Epidemiological Forecast for OAB (2020 - 2030)

4.5.1 Total Prevalent Cases of OAB

4.5.2 Age-Specific Total Prevalent Cases of OAB

4.5.3 Sex-Specific Total Prevalent Cases of OAB

4.5.4 Total Prevalent Cases of OAB by Presentation

4.5.5 Total Prevalent Cases of OAB by Comorbidity

4.5.6 Diagnosed Prevalent Cases of OAB

4.5.7 Age-Specific Diagnosed Prevalent Cases of OAB

4.5.8 Sex-Specific Diagnosed Prevalent Cases of OAB

4.5.9 Diagnosed Prevalent Cases of OAB by Presentation

4.5.10 Diagnosed Prevalent Cases of OAB by Comorbidity

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Insufficient Understanding of Pathophysiological Mechanisms Underlying OAB Subtypes and Lack of Targeted Therapies

7.3 Low Diagnosis Rates

7.4 Efficacy Limitations of Marketed Drugs

7.5 Safety and Tolerability Limitations of Marketed Drugs

7.6 Poor Persistence and Adherence to Drug Treatment

8 R&D Strategies

8.1 Overview

8.1.1 Reliance on Strategic Alliances, Mergers, and Acquisitions

8.1.2 Investment in Novel Molecular Targets and Mechanisms of Action

8.1.3 Alternative Routes of Administration

8.2 Clinical Trials Design

8.2.1 Clinical Trial Protocol

8.2.2 Patient Recruitment

8.2.3 Clinical Trial Endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Late-stage Drugs in Clinical Development

9.2.1 Gene Therapy

9.2.2 P2RX3 Antagonist

9.2.3 Neurite Outgrowth Enhancer

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Second-Line Therapy

10.2.2 Third-Line Therapy

11 Current and Future Players

12 Market Outlook

13 Appendix

Companies Mentioned

• Allergan
• Astellas
• Bayer
• DelNova
• Dompe Farmaceutici
• Dong-A ST Co.
• Ion Channel Innovations
• Johnson & Johnson
• Kissei Pharmaceutical
• Korea United Pharm
• Kyorin Pharmaceutical
• Merck & Co
• Mezzion Pharma
• Pfizer
• Roivant Sciences
• Sinovant Sciences
• Sinsin Pharmaceutical
• Taiho Pharmaceuticals
• TARIS Biomedical
• Urovant Sciences
• Viatris
• XuanZhu Biological Technology Co.

For more information about this report visit https://www.researchandmarkets.com/r/vtybbg

Source: GlobalData

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900